Jeffrey L. Purvin is CEO at RESPONSE BIOMEDICAL CORP (RBM). They have made 3 open-market trades across 1 company since 2012, most recently 2013-12-04.
CIK 0001227578
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
3 open-market purchases totalling $42K since 2012, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| RBM | 5,100 | — |
Shares reported on the most recent Form 4, priced at the 2013-12-05 close. 1 holding could not be priced and is excluded from the total.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.